Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$34.1 million.

  • Autolus Therapeutics' Net Cash Flow rose 6038.49% to -$34.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$538.4 million, marking a year-over-year decrease of 25210.42%. This contributed to the annual value of -$11.3 million for FY2024, which is 9284.31% up from last year.
  • According to the latest figures from Q3 2025, Autolus Therapeutics' Net Cash Flow is -$34.1 million, which was up 6038.49% from $22.4 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Net Cash Flow peaked at $520.4 million during Q1 2024, and registered a low of -$391.5 million during Q4 2024.
  • For the 5-year period, Autolus Therapeutics' Net Cash Flow averaged around -$3.0 million, with its median value being -$35.8 million (2022).
  • Data for Autolus Therapeutics' Net Cash Flow shows a peak YoY increase of 121357.1% (in 2024) and a maximum YoY decrease of 138939.02% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Net Cash Flow stood at $136.7 million in 2021, then surged by 52.42% to $208.3 million in 2022, then tumbled by 112.62% to -$26.3 million in 2023, then plummeted by 1389.39% to -$391.5 million in 2024, then soared by 91.28% to -$34.1 million in 2025.
  • Its last three reported values are -$34.1 million in Q3 2025, $22.4 million for Q2 2025, and -$135.1 million during Q1 2025.